User: prashantiyengar Topic: IP
Category: drugs :: india
Last updated: Dec 19 2014 15:53 IST RSS 2.0
 
1 to 20 of 2,491    
Compulsory Licensing on Patented Drugs 19.12.2014 Govt of india: PIB
So far, one Compulsory License has been granted by the Controller General of Patents, Designs and Trade Marks for the anti-cancer drug containing the compound ‘Sorafenib Tosylate’ which is used for treatment of kidney and liver cancer to a drug manufacturing company, namely M/s Natco Pharma Ltd.
Also found in: [+]
HC reserves order on Novartis-Cipla drug dispute 17.12.2014 ET: Pharma
The Delhi High Court has reserved its verdict on a dispute between pharma firms Novartis and Cipla over manufacturing of the drug Indacaterol, used for treatment of chronic obstructive pulmonary disease.
Also found in: [+]
Novartis sues Cipla over respiratory drug Onbrez 17.12.2014 Rediff: Business
Novartis said it is partnered with generic drugmaker Lupin Ltd to sell the drug in India
Also found in: [+]
Novartis moves court seeking to restrain Cipla from selling respiratory drug Onbrez 17.12.2014 ET: Pharma
Experts say that the MNC's stand is a clear violation of IP laws, which stipulate that the patent has to be 'locally worked' — that is, be affordable.
Also found in: [+]
Novartis drags Cipla to court 17.12.2014 TOI: India Business
Drug MNC Novartis has moved the Delhi high court seeking to restrain generic firm Cipla from selling an affordable version of its respiratory drug Onbrez in the domestic market.
Also found in: [+]
India-led BRICS opposes UN arm’s move on model drug law 15.12.2014 ET: Policy
UNODC had last week held closed-door meetings in Vienna to firm up a model law prescribing harsh penalties for ‘falsified’ drug-related crimes.
Also found in: [+]
Government may not act on Cipla’s patent plea 15.12.2014 TOI: India Business
In a setback to Cipla, the homegrown generics medicine company, the government has so far found little merit in its plea for waiver and cancellation of patent rights for five drugs over which Novartis has exclusive rights.
Also found in: [+]
Ahead of Obama visit, US rules out embargo, lets India off IPR hook 14.12.2014 TOI: India
The fear of US sanctions over India’s intellectual property rights regime has lifted, at least for the moment, with Washington giving a clean chit after a special ...
Also found in: [+]
Let India make cheap drugs 14.12.2014 Sify Finance
Last month, the United States and India announced an important breakthrough concerning India's "right-to-food" programme. The Indian government subsidises food for its poorest citizens
Also found in: [+]
Nexavar Licence Case: SC dismisses Bayer’s appeal against HC decision 13.12.2014 ET: Pharma
Bombay HC in July refused to revoke a compulsory licence issued to India’s Natco Pharma to sell a version of the German drug major’s kidney-cancer drug Nexavar
Also found in: [+]
Increasing patenting activity seen in India: Survey 12.12.2014 ET: Indicators
Computing & control technology sector has drawn level with pharma sector with each taking 17% of overall share of Indian innovation, report said.
Also found in: [+]
Cadila launches first cheaper copy of world's top-selling drug 9.12.2014 Sify Finance
Also found in: [+]
UN Office on Drugs and Crime scheduled to meet to firm up model law 8.12.2014 ET: Pharma
India is not part of the UNODC expert group, but as one of the largest generic drugs suppliers, its supply chain may face direct consequences.
Also found in: [+]
Japan seeks patent term extension at Regional Comprehensive Economic Partnership 5.12.2014 ET: Foreign Trade
RCEP is a proposed free trade agreement among the 10-member Association of Southeast Asian Nations and Australia, China, India, Japan, South Korea and New Zealand.
Also found in: [+]
Panel to draft intellectual property policy riddled with conflict of interest 1.12.2014 TOI: India
Increased focus on India’s intellectual property and patent law has put the spotlight on the IP think tank set up by the Department of Industrial Policy and Promotion (DIPP). It is a six-member panel with zero representation from independent academicians working on the subject and none from civil society groups working on public interest ramifications of intellectual property ...
Also found in: [+]
MNCs deprive India of vital drugs despite getting monopoly rights 30.11.2014 ET: Pharma
Japanese firm Otsuka Pharmaceuticals, Myers-Squibb, Novartis are deferring launch of medicines critical for treatment of serious non-communicable diseases.
Also found in: [+]
MNCs deprive India of vital drugs 30.11.2014 TOI: Home
Some multinational companies have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law.
Also found in: [+]
US urges India to look beyond IPR in affordable healthcare 26.11.2014 Sify Finance
India was Tuesday urged by the US to look beyond intellectual property rights (IPR) and compulsory licensing in affordable healthcare, and to address concerns like tariff reduction, distribution of medicines and insurance coverage.
Also found in: [+]
US urges India to toughen patent laws to draw investors 25.11.2014 ET: Policy
Without an Indian focus on patent protection, "there will be no pipeline of drugs to be made into generics after a certain time," US Trade Representative Michael Froman said in New Delhi.
Also found in: [+]
Modi urged to stand up to US pressure to change patent law 25.11.2014 TOI: India Business
US Trade Representative meeting high-ranking Indian officials during his India visit is worrying public health activists that he will pressurise the government to weaken India's patent law which is seen to be pro-public health, with in-built safeguards that prevent pharma companies from getting extensions on patents by tweaking existing molecules and claiming them to be innovation.
Also found in: [+]
1 to 20 of 2,491